MOLECULAR PARTNERS ADS/1 (F:6ML0) — Market Cap & Net Worth
Market Cap & Net Worth: MOLECULAR PARTNERS ADS/1 (6ML0)
MOLECULAR PARTNERS ADS/1 (F:6ML0) has a market capitalization of $133.19 Million (€113.92 Million) as of October 10, 2026. Listed on the F stock exchange, this Germany-based company holds position #18131 globally and #1684 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MOLECULAR PARTNERS ADS/1's stock price €3.54 by its total outstanding shares 37411668 (37.41 Million).
MOLECULAR PARTNERS ADS/1 Market Cap History: 2021 to 2026
MOLECULAR PARTNERS ADS/1's market capitalization history from 2021 to 2026. Data shows change from $752.30 Million to $137.34 Million (-26.36% CAGR). Check MOLECULAR PARTNERS ADS/1 (6ML0) share price today for real-time trading data and today's change.
MOLECULAR PARTNERS ADS/1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MOLECULAR PARTNERS ADS/1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see cash efficiency ratio of MOLECULAR PARTNERS ADS/1 for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
43.83x
MOLECULAR PARTNERS ADS/1's market cap is 43.83 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $752.30 Million | $9.33 Million | -$63.78 Million | 80.63x | N/A |
| 2022 | $242.75 Million | $189.56 Million | $117.85 Million | 1.28x | 2.06x |
| 2023 | $165.33 Million | $7.04 Million | -$61.98 Million | 23.49x | N/A |
| 2024 | $217.82 Million | $4.97 Million | -$54.04 Million | 43.83x | N/A |
Competitor Companies of 6ML0 by Market Capitalization
Companies near MOLECULAR PARTNERS ADS/1 in the global market cap rankings as of October 10, 2026. See 6ML0 net asset quality score to understand what proportion of total assets are financed by equity.
Key companies related to MOLECULAR PARTNERS ADS/1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $129.29 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #366 globally with a market cap of $75.50 Billion USD.
- CSL Ltd (AU:CSL): Ranked #448 globally with a market cap of $63.11 Billion USD ( AU$89.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $129.29 Billion | $510.08 |
| #366 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $75.50 Billion | $746.54 |
| #448 | CSL Ltd | AU:CSL | $63.11 Billion | AU$183.84 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $225.00 |
MOLECULAR PARTNERS ADS/1 Historical Marketcap From 2021 to 2026
Between 2021 and today, MOLECULAR PARTNERS ADS/1's market cap moved from $752.30 Million to $ 137.34 Million, with a yearly change of -26.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €137.34 Million | -15.14% |
| 2025 | €161.83 Million | -25.70% |
| 2024 | €217.82 Million | +31.75% |
| 2023 | €165.33 Million | -31.89% |
| 2022 | €242.75 Million | -67.73% |
| 2021 | €752.30 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of MOLECULAR PARTNERS ADS/1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $133.19 Million USD |
| MoneyControl | $133.19 Million USD |
| MarketWatch | $133.19 Million USD |
| marketcap.company | $133.19 Million USD |
| Reuters | $133.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About MOLECULAR PARTNERS ADS/1
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more